Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Operating Costs and Expenses:
General and administrative	$ 15,447	$ 7,396
Research and development	8,604	12,031
In-process research and development impairment	0	1,325
Goodwill impairment		5,594
Total Operating Costs and Expenses	24,051	26,346
Loss from Operations	(24,051)	(26,346)
Other Income:
Foreign currency exchange gain (loss)	25	(4)
Interest income	287	697
Total Other Income	312	693
Net Loss before income taxes	(23,739)	(25,653)
Income tax benefit
Net Loss	(23,739)	(25,653)
Less deemed dividend from warrant inducement	(1,510)
Net Loss Attributable to Common Stockholders	$ (25,249)	$ (25,653)
Net Loss Per Share - Basic (in dollars per share)	$ (2.08)	$ (19.03)
Net Loss Per Share - Dilutive (in dollars per share)	$ (2.08)	$ (19.03)
Weighted average number of shares outstanding during the period - Basic (in shares)	12,140,697	1,348,126
Weighted average number of shares outstanding during the period - Dilutive (in shares)	12,140,697	1,348,126
Net Loss	$ (23,739)	$ (25,653)
Gain (loss) on foreign currency translation	1,933	(1,210)
Total comprehensive loss	$ (21,806)	$ (26,863)